Ocugen Reports Progress in Q1 2025 with Advancements in Gene Therapy

Ocugen (OCGN) - 1Q25 Reported With All Three Main Clinical Trials On Schedule - Channelchek

Monday, May 12, 2025 Ocugen, Inc. is a biotechnology company focused on developing and commercializing novel gene therapies, biologicals, and vaccines. The lead product in its gene therapy program, OCU400, is in Phase 1/2 clinical trials for retinitis pigmentosa. Robert LeBoyer, Senior Vice President, Equity Research Analyst, Biotechnology, Noble Capital Markets, Inc. Refer to the full report for the price target, fundamental analysis, and ratin…

Ocugen Reports Progress in Q1 2025 with Advancements in Gene Therapy

MALVERN, PA — Ocugen, Inc. (NASDAQ: OCGN) has reported its first-quarter 2025 financial results and shared updates on its growing pipeline of gene therapy treatments aimed at combating significant unmet medical needs. The company achieved progress across its gene therapy portfolio, with its OCU400 Phase 3 trial for retinitis pigmentosa (RP) moving steadily toward potential Biologics License Application (BLA) and Marketing Authorization Applicati…